Previous studies have reported that NCAPG is a promising therapeutic target across different tumor types, and it may be associated with development and progression of hepatocellular carcinoma (HCC) [25, 26], esophageal squamous cell carcinoma (ESCC) [27], colorectal cancer (CRC) [28], breast cancer (BC) [29], prostate cancer (PCa) [30], kidney renal papillary cell carcinoma (KIRP) [31], endometrial cancer (EC) [32], bladder cancer (BLCA) [33], gastric cancer (GC) [34], glioblastoma (GBM) [35], and so on. The gene discussed is NCAPG; the disease is bladder transitional cell carcinoma.